Patents by Inventor John W. Cherwonogrodzky
John W. Cherwonogrodzky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10081672Abstract: The present invention relates to anti-ricin antibodies and uses thereof. More specifically, the invention relates to anti-ricin antibodies and fragments thereof as well as their use in therapy or prophylaxis.Type: GrantFiled: April 1, 2016Date of Patent: September 25, 2018Assignee: National Research Council of CanadaInventors: Wei-Gang Hu, Laurel M. Negrych, Damon Chau, Junfei Yin, Scott J. Jager, John W. Cherwonogrodzky
-
Patent number: 9982040Abstract: The present invention relates to anti-ricin antibodies and uses thereof. More specifically, the invention relates to anti-ricin antibodies and fragments thereof as well as their use in therapy or prophylaxis.Type: GrantFiled: April 1, 2016Date of Patent: May 29, 2018Assignee: Her Majesty The Queen in Right of Canada, As Represented by the Minister of National DefenceInventors: Wei-Gang Hu, Laurel M. Negrych, Damon Chau, Junfei Yin, Scott J. Jager, John W. Cherwonogrodzky
-
Publication number: 20160280773Abstract: The present invention relates to anti-ricin antibodies and uses thereof. More specifically, the invention relates to anti-ricin antibodies and fragments thereof as well as their use in therapy or prophylaxis.Type: ApplicationFiled: April 1, 2016Publication date: September 29, 2016Applicant: Her Majesty the Queen in Right of Canada, as represented by the Minister of National DefenceInventors: Wei-Gang HU, Laurel M. NEGRYCH, Damon CHAU, Junfei YIN, Scott J. JAGER, John W. CHERWONOGRODZKY
-
Publication number: 20160207998Abstract: The present invention relates to anti-ricin antibodies and uses thereof. More specifically, the invention relates to anti-ricin antibodies and fragments thereof as well as their use in therapy or prophylaxis.Type: ApplicationFiled: April 1, 2016Publication date: July 21, 2016Applicant: Her Majesty the Queen in Right of Canada, as represented by the Minister of National DefenceInventors: Wei-Gang HU, Laurel M. NEGRYCH, Damon CHAU, Junfei YIN, Scott J. JAGER, John W. CHERWONOGRODZKY
-
Patent number: 9309305Abstract: The present invention relates to anti-ricin antibodies and uses thereof. More specifically, the invention relates to anti-ricin antibodies and fragments thereof as well as their use in therapy or prophylaxis.Type: GrantFiled: January 31, 2012Date of Patent: April 12, 2016Assignee: National Research Council of CanadaInventors: Wei-Gang Hu, Laurel M Negrych, Damon Chau, Junfei Yin, Scott J. Jager, John W. Cherwonogrodzky
-
Publication number: 20140093504Abstract: The present invention relates to anti-ricin antibodies and uses thereof. More specifically, the invention relates to anti-ricin antibodies and fragments thereof as well as their use in therapy or prophylaxis.Type: ApplicationFiled: January 31, 2012Publication date: April 3, 2014Applicant: Her Majesty The Queen In Right Of Canada, as repre sented by the Minister of National DefenceInventors: Wei-Gang Hu, Laurel M Negrych, Damon Chau, Junfei YIN, Scott J. Jager, John W. Cherwonogrodzky
-
Publication number: 20080176270Abstract: This invention discloses methods for identifying Francisella tularensis vaccine candidates. It enables identification of novel vaccine candidates and quality assurance for vaccine batches, assessment of protection in vaccinates and identification of the infecting agent in vaccinates. Mice were first vaccinated with Brucella abortus O-polysaccharide (OPS) vaccine. These animals were then given 10 LD50s of F. tularensis live vaccine strain (LVS). Sixty percent (60%) of the vaccinated mice survived the multiple lethal doses. Sera were collected from these surviving mice and the antibodies were used to probe supernatant and cell lysates of live F. tularensis LVS cultures. Several F. tularensis components were identified only by the noted “survivor” antisera. Of these identified proteins, enzyme digestions and chemical oxidation suggest post-translational modifications of some proteins e.g. a 52 kDa glycoprotein, a 45 kDa lipoprotein and a 19 kDa nucleoprotein.Type: ApplicationFiled: October 31, 2007Publication date: July 24, 2008Applicants: of Her Majesty's Canadian Gov'tInventors: Christopher Sikora, Bradley J. Berger, John W. Cherwonogrodzky
-
Publication number: 20040151736Abstract: This invention discloses methods for identifying Francisella tularensis vaccine candidates. It enables identification of novel vaccine candidates and quality assurance for vaccine batches, assessment of protection in vaccinates and identification of the infecting agent in vaccinates. Mice were first vaccinated with Brucella abortus O-polysaccharide (OPS) vaccine. These animals were then given 10 LD50s of F. tularensis live vaccine strain (LVS). Sixty percent (60%) of the vaccinated mice survived the multiple lethal doses. Sera were collected from these surviving mice and the antibodies were used to probe supernatant and cell lysates of live F. tularensis LVS cultures. Several F. tularensis components were identified only by the noted “survivor” antisera. Of these identified proteins, enzyme digestions and chemical oxidation suggest post-translational modifications of some proteins e.g. a 52 kDa glycoprotein, a 45 kDa lipoprotein and a 19 kDa nucleoprotein.Type: ApplicationFiled: January 23, 2004Publication date: August 5, 2004Inventors: Christopher A. Sikora, Bradley J. Berger, John W. Cherwonogrodzky
-
Patent number: 6582699Abstract: A vaccine comprising a combination of Brucella “A” and “M” outer-polysaccharides (OPSs) and “R” protein antigens for enhancing immunity against brucellosis is disclosed. The OPS may be obtained from different strains or species of Brucellae (i.e. combining OPS extracted from different bacteria expressing “A” or “M” OPS, or combining OPS and OPS-protein complexes extracted from different bacteria). The OPS or OPS-protein complexes may also be obtained from a single strain expressing more than one OPS (e.g. from B. suis strain 145 which expresses “A”, “M” and possibly other OPSs). The vaccine according to the present invention overcomes the limitation of previously discovered B. abortus “A” OPS which only protects against species and strains of Brucella that had “A” OPS but not against others with different OPS.Type: GrantFiled: December 14, 2000Date of Patent: June 24, 2003Assignee: Her Majesty the Queen in right of Canada, as represented by the Minister of National Defence in her Brittanic Majesty's Government of the United Kingdom of Great Britain and Northern IrelandInventor: John W. Cherwonogrodzky
-
Publication number: 20020122808Abstract: A vaccine comprising a combination of Brucella “A” and “M” outer-polysaccharides (OPSs) and “R” protein antigens for enhancing immunity against brucellosis is disclosed. The OPS may be obtained from different strains or species of Brucellae (i.e. combining OPS extracted from different bacteria expressing “A” or “M” OPS, or combining OPS and OPS-protein complexes extracted from different bacteria). The OPS or OPS-protein complexes may also be obtained from a single strain expressing more than one OPS (e.g. from B. suis strain 145 which expresses “A”, “M” and possibly other OPSs). The vaccine according to the present invention overcomes the limitation of previously discovered B. abortus “A” OPS which only protects against species and strains of Brucella that had “A” OPS but not against others with different OPS.Type: ApplicationFiled: December 14, 2000Publication date: September 5, 2002Inventor: John W. Cherwonogrodzky
-
Patent number: 6444210Abstract: The present invention relates to the effects of bacterial polysaccharides on cell mediated immunity in animals. Polysaccharides of the present invention comprise the outer polysaccharides (OPS) located on bacterial cell membranes and other polysaccharides (e.g. “Poly B”) either secreted or contained within the periplasmic space. These polysaccharides have been found to enhance the general or cell mediated immunity of animals to various diseases. The invention provides for the use of such polysaccharides in preventing and treating various infections as well as in treating carcinomas. The invention also provides for synthetic polysaccharides having the same immuno-modulating effect as the bacterial polysaccharides.Type: GrantFiled: June 25, 1997Date of Patent: September 3, 2002Assignee: Her Majesty the Queen in right of Canada, as represented by the Minister of National Defence of Her Majesty′s Canadian GovermentInventors: Bill Kournikakis, Maureen L. Simpson, John W. Cherwonogrodzky
-
Patent number: 6436652Abstract: A bacteriophage linked to an enzyme can replace an antibody in a system for detecting the presence of a bacteria in a sample. Specifically Brucella abortus (a pathogen which causes brucellosis in cattle) can be detected using Brucella bacteriophage for the virus, urease for the enzyme linked to the bacteriophage, m-maleimidobenzoyl-N-hydrosysuccimide ester as a coupling reagent, sera from mice immunized with Brucella bacteriophage for a detector antibody, urease conjugated to anti-mouse sheep antibody for an indicator, and urea with bromcresol purple as the substrate. The materials can be used in indirect (sandwich) or direct enzyme-linked viral assays (ELVirA).Type: GrantFiled: August 18, 1999Date of Patent: August 20, 2002Assignee: Her Majesty the Queen in right of Canada, as represented by the Minister of National Defence of Her Majesty's Canadian GovernmentInventors: John W. Cherwonogrodzky, Kamil Lotfali
-
Publication number: 20020081642Abstract: A serodiagnostic assay for fungal and yeast antibodies in animal and human test subjects is disclosed. The assay is comprised of preparing fungal and yeast cell culture supernatants mixture, reacting the cell culture supernatants with sera from a test subject, and determining the serum antibody level of the test subject. The present invention also discloses some unique characteristics of yeast and fungal supernatants which enhance the accuracy and efficacy of the serodiagnostic assay of the invention.Type: ApplicationFiled: May 30, 2001Publication date: June 27, 2002Inventor: John W. Cherwonogrodzky
-
Patent number: 6355445Abstract: A bacteriophage linked to an enzyme can replace an antibody in a system for detecting the presence of a bacteria in a sample. Specifically Brucella abortus (a pathogen which causes brucellosis in cattle) can be detected using Brucella bacteriophage for the virus, urease for the enzyme linked to the bacteriophage, m-maleimidobenzoyl-N-hydrosysuccimide ester as a coupling reagent, sera from mice immunized with Brucella bacteriophage for a detector antibody, urease conjugated to anti-mouse sheep antibody for an indicator, and urea with bromcresol purple as the substrate. The materials can be used in indirect (sandwich) or direct enzyme-linked viral assays (ELVirA).Type: GrantFiled: August 11, 1995Date of Patent: March 12, 2002Assignee: Her Majesty the Queen in right of Canada, as represented by the Minister of National DefenceInventors: John W. Cherwonogrodzky, Kamil Lotfali
-
Publication number: 20010055780Abstract: A bacteriophage linked to an enzyme can replace an antibody in a system for detecting the presence of a bacteria in a sample. Specifically Brucella abortus (a pathogen which causes brucellosis in cattle) can be detected using Brucella bacteriophage for the virus, urease for the enzyme linked to the bacteriophage, m-maleimidobenzoyl-N-hydrosysuccimide ester as a coupling reagent, sera from mice immunized with Brucella bacteriophage for a detector antibody, urease conjugated to anti-mouse sheep antibody for an indicator, and urea with bromcresol purple as the substrate. The materials can be used in indirect (sandwich) or direct enzyme-linked viral assays (ELVirA).Type: ApplicationFiled: August 11, 1995Publication date: December 27, 2001Inventors: JOHN W. CHERWONOGRODZKY, KAMIL LOTFALI
-
Patent number: 5951987Abstract: A vaccine comprising purified outer-polysaccharide (OPS) is effective for protection against brucellosis. The vaccine is derived from Brucella or a variety of cross reactive bacteria. The vaccine can be administered by different routes (intramuscularly, subcutaneously, intraperitoneally, orally). The vaccine is effective in protecting against other infectious bacteria, aside from Brucella. It is likely that the vaccine can be given after infection to reduce illness.Type: GrantFiled: September 16, 1996Date of Patent: September 14, 1999Assignee: Her Majesty the Queen as represented by the Minister of National Defence of Her Majesty'Canadian GovernmentInventors: John W. Cherwonogrodzky, Jonathan P. Wong, Vincent L. Di Ninno
-
Patent number: 5006463Abstract: A method is disclosed for discriminating between cattle vaccinated against and those infected with Brucella spp. The method involves immunoassay using a purified polysaccharide containing 4,6-dideoxy-4-acylamido-D-mannopyranosyl units obtained from B. abortus or from cross-reacting organisms, and results in improved differentiation between vaccinated and infected animals. Test kits are also disclosed for performing the assay and a process is disclosed for obtaining the O-chain polysaccharides in high purity and yield.Type: GrantFiled: September 25, 1987Date of Patent: April 9, 1991Assignee: National Research Council of CanadaInventors: John W. Cherwonogrodzky, J. Robert Duncan, Klaus Nielsen, Peter F. Wright, David R. Bundle, Malcolm B. Perry
-
Patent number: 4831126Abstract: The antigenic O-chain polysaccharides from Brucella abortus and Yersinia enterocolitica serotype 0:9 have similar structure, i.e. 1-2 linked 4,6-dideoxy-4-formamido-.alpha.-D-mannopyranosyl units. The antigen is more readily isolated from the Yersinia and may be chemically modified to have a hydrophobic moiety attached thereto. The antigen can be adsorbed or coupled to carriers suitable for immunoassay use such as ELISA and RIA. A monoclonal antibody capable of specifically binding to B. abortus and Y. enterocolitica, has been produced. Assay procedures and kits therefor, are described.Type: GrantFiled: February 26, 1985Date of Patent: May 16, 1989Assignee: Canadian Patents & Development Ltd.Inventors: David R. Bundle, Malcolm B. Perry, John W. Cherwonogrodzky, J. Robert Duncan, Martine G. Caroff